Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort
Guadalupe Oñate, Marta Pratcorona, Ana Garrido, Alícia Artigas-Baleri, Álex Bataller, Mar Tormo, Montserrat Arnán, Susana Vives, Rosa Coll, Olga Salamero, Ferran Vall‐Llovera, Antònia Sampol, Antoni García, Marta Cervera, Sara Garcia-Ávila, Joan Bargay, Xavier Ortı́n, Josep Nomdedéu, Jordi Esteve, Jorge Sierra, Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM)
Abstract
Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3mut). We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098). Patients were divided into an early (2012-2015) and late (2016-2020) cohorts. They were uniformly treated except for the addition of midostaurin in 71% of late group patients. No differences were observed in response rates or the number of allotransplants between groups. Outcome was improved in the late period: 2-year relapse incidence decreased from 42% vs 29% in early vs late group (p = 0.024) and 2-year overall survival (OS) improved from 47% vs 61% (p = 0.042), respectively. The effect of midostaurin was evident in NPM1mut patients (n = 151), with 2-yr OS of 72% (exposed) vs 50% (naive) patients (p = 0.011) and mitigated FLT3-ITD allelic ratio prognostic value: 2-yr OS with midostaurin was 85% and 58% in low and high ratio patients (p = 0.049) vs 67% and 39% in naive patients (p = 0.005). In the wild-type NPM1 subset (n = 75), we did not observe significant differences between both study periods. In conclusion, this study highlights the improved outcome of FLT3mut AML fit patients with the incorporation of midostaurin.